MRFF 2022 National Critical Research Infrastructure Program

What is the MRFF 2022 National Critical Research Infrastructure Program?

The MRFF 2022 National Critical Research Infrastructure Program is a grant opportunity to help organisations and researchers to collaborate on research infrastructure projects that translate into health benefits for Australians.

Background

The 2022 National Critical Research Infrastructure grant is part of the Medical Research Future Fund (MRFF) and the National Critical Research Infrastructure Initiative. This 3 stream program will fund organisations to undertake innovative project solutions to complex health problems in areas of unmet need to improve Australian’s quality of life and the health system sustainability.

Objectives

The successful organisations aim to improve health outcomes, by:

enhancing Australia’s research infrastructure
addressing areas of unmet need in the research sector through greater access to quality data and health interventions
utilising investment through greater collaboration with industry, government and medical sector to enable research to be translated into greater health benefits.

The objective of this program is to provide grants to Australian medical research and innovation projects that align with the following streams:

Stream 1

Address an area of unmet need by promoting the development and implementation of new research methodologies or applications including ‘omics’-led approaches and enhanced infrastructure linkage strategies by supporting development and/or expansion of research enablers such as:

biobanks
tissue repositories
novel platforms
secure health data environments to create valuable research resources.

Stream 2

Develop and translate into practice:

digital therapeutics
artificial intelligence enabled health interventions and technologies (eg wearables integrated into clinical practice)
applications or other software for use in clinical practice.

Stream 3

Utilise co-investment with the research sector, state and territory governments and industry in significant critical research infrastructure (eg facilities and equipment) to support:

development of research capacity
capability and/or effectiveness in an area of need
easily accessible facilities and platforms for the wider research community, including within industry.

Funding

For this grant opportunity, up to $73 million is available over two years from 2022-23 for the three Streams.

$53 million in 2022-23 ($8 million in Stream 1, $8 million in Stream 2, $30 million in Stream 3, $7 million for all Streams)
$20 million in 2023-24 ($7 million in Stream 1, $7 million in Stream 2, $6 million for both Streams).

Eligible Projects

The MRFF 2022 National Critical Research Infrastructure Program can only accept applications that provide:

a list of up to 15 chief investigators using the mandatory templates on business.gov.au – with none of these people permitted to be listed on any other application
evidence from your board (or chief executive officer or equivalent if there is no board) that the project is supported, that you can complete the project and meet any costs not covered by grant funding
letters of support from each project partner/consortia partner
a detailed project plan (max 12 pages)
a detailed project budget
a one-page statement of how your project will contribute to the Measures of Success for the MRFF as described in the MRFF Evaluation, Monitoring and Learning Strategy
a detailed risk management plan (max 2 pages)
details of IP arrangements if not included within the written content of the application

Eligible Applicants

You can apply if you:

have an Australian business number (ABN)
are incorporated in Australia

You must also be one of the following entities:

a medical research institute
a university
a corporate Commonwealth entity
a corporation (including businesses and not for profits).

You can partner with one or more other organisations but you must decide who the lead organisation is. Stream 3 applicants must have at least one partner from an academic organisation and another from industry or state/territory government.

The lead organisation must fill out the application form and enter into the grant agreement with the Commonwealth.

Timing

Applications close 7 September 2022.

More Information

What is the #1 grant for start-ups?

12,000+ companies access the R&D tax incentive per year that yields a CASH REBATE of up to 43.5%.
This might be perfect your start up.
Do you want to know more?

Bulletpoint is a Melbourne-based consultancy specialising in guiding businesses through the complex process of the R&D tax incentive. With a decade of experience under our belt, we’re proud to be led by Australia’s highest-rated R&D tax consultant. We’ve successfully lodged over 500 R&D claims, demonstrating a proven track record.

Our approach is straightforward and personable, focusing on cutting through the jargon to help businesses truly understand the definition of R&D in government terms. We’re passionate about what we do, and our clients appreciate this, often commenting on the difference our expertise has made to their businesses. They’ve praised us for uncovering grants they wouldn’t have otherwise known about and for making the whole process less stressful for them.

We’re proud to have an average rating of 4.8 stars from over 250 Google reviews. Despite our success, we continue to strive for improvement, learning from every piece of feedback we receive.

At Bulletpoint, we excel in helping businesses navigate the complexities of the R&D tax incentive process, ensuring they reap the benefits they deserve. As experts in our field, we’re well-versed in what works and what doesn’t when it comes to aligning businesses’ perceptions of R&D with the government’s eligibility criteria.

So, if you’re looking for accessible expertise and a proven success rate, you’ll find it with us at Bulletpoint. We’re ready to guide you through the R&D tax incentive process with a blend of professionalism and personality, ensuring your experience with us is not just successful, but enjoyable as well.